BioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell

MT Newswires Live12-08

BioNTech (BNTX) and OncoC4 said Saturday that their experimental therapy, gotistobart, showed a "meaningful" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.

The study included 45 patients receiving gotistobart monotherapy and 42 patients receiving chemotherapy, or docetaxel.

At 12 months, overall survival rate was 63% for gotistobart versus 30% for chemotherapy. At a median follow-up of 14.5 months, patients in the gotistobart treatment arm had not yet reached the median overall survival, while the docetaxel arm achieved a median overall survival of 10 months.

Gotistobart reduced the risk of death by 54% compared with chemotherapy, the companies said.

The pivotal stage of the phase 3 trial is ongoing at more than 160 sites globally.

BioNTech shares were up 3.2% in recent premarket activity Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589308483?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589308483","market":"nz","top_or_hot":-1,"title":"BioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> BioNTech (BNTX) and OncoC4 said Saturday that their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.</p><p>The study included 45 patients receiving gotistobart monotherapy and 42 patients receiving chemotherapy, or docetaxel.</p><p>At 12 months, overall survival rate was 63% for gotistobart versus 30% for chemotherapy. At a median follow-up of 14.5 months, patients in the gotistobart treatment arm had not yet reached the median overall survival, while the docetaxel arm achieved a median overall survival of 10 months.</p><p>Gotistobart reduced the risk of death by 54% compared with chemotherapy, the companies said.</p><p>The pivotal stage of the phase 3 trial is ongoing at more than 160 sites globally.</p><p>BioNTech shares were up 3.2% in recent premarket activity Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioNTech (BNTX) and OncoC4 said Saturday that their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.</p><p>The study included 45 patients receiving gotistobart monotherapy and 42 patients receiving chemotherapy, or docetaxel.</p><p>At 12 months, overall survival rate was 63% for gotistobart versus 30% for chemotherapy. At a median follow-up of 14.5 months, patients in the gotistobart treatment arm had not yet reached the median overall survival, while the docetaxel arm achieved a median overall survival of 10 months.</p><p>Gotistobart reduced the risk of death by 54% compared with chemotherapy, the companies said.</p><p>The pivotal stage of the phase 3 trial is ongoing at more than 160 sites globally.</p><p>BioNTech shares were up 3.2% in recent premarket activity Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589308483","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589308483","pubTimestamp":1765195597,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioNTech  and OncoC4 said Saturday that their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.The study included 45 patients receiving gotistobart monotherapy and 42 patients receiving chemotherapy, or docetaxel.At 12 months, overall survival rate was 63% for gotistobart versus 30% for chemotherapy. At a median follow-up of 14.5 months, patients in the gotistobart treatment arm had not yet reached the median overall survival, while the docetaxel arm achieved a median overall survival of 10 months.Gotistobart reduced the risk of death by 54% compared with chemotherapy, the companies said.The pivotal stage of the phase 3 trial is ongoing at more than 160 sites globally.BioNTech shares were up 3.2% in recent premarket activity Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"BioNTech、OncoC4表示肺癌3期试验显示出“有意义的”总体生存益处；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"BioNTech (BNTX) and OncoC4 said Saturday that their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.The study included 45 patients receiving gotistobart monotherapy and 42 patients receiving chemotherapy, or docetaxel.At 12 months, overall survival rate was 63% for gotistobart versus 30% for chemotherapy. At a median follow-up of 14.5 months, patients in the gotistobart treatment arm had not yet reached the median overall survival, while the docetaxel arm achieved a median overall survival of 10 months.Gotistobart reduced the risk of death by 54% compared with chemotherapy, the companies said.The pivotal stage of the phase 3 trial is ongoing at more than 160 sites globally.BioNTech shares were up 3.2% in recent premarket activity Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589308483","isCrawlerRequest":true}